Actuate Therapeutics

Oncology therapies with survival benefit typically command strong pricing relative to cost of care. If elraglusib is ultimately approved, especially with orphan or pediatric rare‑disease incentives, pricing power could be meaningful.

However, PDAC first‑line therapy now includes the NALIRIFOX (Onivyde) regimen, and any elraglusib combination must show clear incremental value versus established standards to maintain price and access. Until confirmatory data and payer negotiations are known, pricing power remains latent rather than demonstrated.